RET receptor tyrosine kinase promotes breast cancer metastasis to the brain and RET inhibitors pralsetinib and selpercatinib suppress breast cancer brain metastases - PubMed
4 hours ago
- #breast cancer brain metastasis
- #RET tyrosine kinase
- #RET inhibitors
- RET receptor tyrosine kinase activation is elevated in breast cancer brain metastases (BCBM) compared to primary tumors.
- High RET pathway activation correlates with worse brain metastasis-free survival in HER2-enriched and triple-negative breast cancer (TNBC) patients.
- RET promotes breast cancer metastasis to the brain and enhances brain tumor formation in mouse models.
- RET inhibitors pralsetinib and selpercatinib reduce viability, increase apoptosis, and inhibit migration of brain-tropic breast cancer cells in vitro.
- In mouse studies, RET inhibition prevents brain metastasis formation and suppresses growth of intracranial tumors.